Treatment of Recurrent/Metastatic Head and Neck Cancer

This study is a Phase Ib/II study of TQB2922 injection (subcutaneous). In the Phase Ib stage, a 3+3 dose-escalation design was used to determine the RP2D and pharmacokinetic characteristics of TQB2922 injection (subcutaneous) administered once every 3 weeks in subjects with R/M HNC. The Phase II stage explored the efficacy and safety of TQB2922 (subcutaneous) as monotherapy or in combination therapy in subjects with R/M HNC.

NCT Number	NCT07601204
Lead Sponsor	Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Conditions	Recurrent/Metastatic Head and Neck Cancer
Enrollment	128 participants
Start Date	2026-06
Primary Completion	2029-02 (estimated)
Study Completion	2030-12 (estimated)
Updated on ClinicalTrials.gov	2026-05-22